Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02088580 |
Recruitment Status :
Completed
First Posted : March 17, 2014
Last Update Posted : October 2, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Psychotic Unipolar Depression Bipolar Depression | Procedure: Triple Chronotherapy | Not Applicable |
Acute depression, and suicidality continue to be significant causes of morbidity and mortality, and frequently result in acute inpatient hospitalization. Currently available treatments for depression have limitations for acute care including, either a slow onset of action such as is the case of pharmacotherapy, or high cost and limited availability such as is the case for ECT. This is exacerbated by ever shortening hospitalization times. Subsequently many of the individuals who are admitted for depression are discharged weeks before it can be expected for them to have symptomatic relief. Further more, in many cases treatment results in the trial of multiple medications before an effective treatment regimen is found (if such a treatment is found at all) (Rush, Trivedi et al. 2006). There is subsequently a great need for effective anti-depressant therapies with rapid onset of action, widespread availability, and cost effectiveness.
There is a consistent and expanding body of literature showing that chronotherapy is an effective, and rapid treatment of acute depression(Wu, Kelsoe et al. 2009, Martiny, Refsgaard et al. 2012, Echizenya, Suda et al. 2013). Published studies report response and remission rates in the range of 41-61%, 24-59% respectively acutely. Chronotherapy is a brief protocol that involves the combination of wake therapy (total sleep deprivation), sleep phase advance (a shift to an earlier sleep schedule with gradual normalization), and bright light therapy. The currently published reports have demonstrated efficacy in both unipolar and bipolar depression, and there has been reported stability of results for as long as 9 weeks (which was the longest designed study). Studies have been completed in real world clinical populations, which have included co-morbid populations, with the only groups showing a worsening of effect being those with psychotic depression (Benedetti, Zanardi et al. 1999), and those with panic disorder(Roy-Byrne, Uhde et al. 1986). The treatment itself has been well tolerated with a high percentage of individuals completing the procedure.
The current body of literature is encouraging, and the technique is being utilized clinically in some facilities (including our own institution), however there are still relatively few clinical trials published, and still unanswered questions that limit widespread clinical utility. One such issue is related to the high percentage of published trials performed outside of the US (although some have been done in the US). Because a high percentage of the studies have been done in other countries it is not clear if this procedure will translate well into the treatment paradigm in the US. Currently in the US, inpatient admission is restricted to individuals with severe, often highly treatment resistant disease that includes acute suicidality. To this writers knowledge there have not been any studies that specifically address suicidality. It is also not clear if patients in the US will tolerate the procedure. Tolerability has been addressed in many of the published papers, and in general the procedure is tolerated well with few if any side effects, however, again it is unclear how the procedure would be tolerated in clinical patients in the US.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients |
Study Start Date : | October 2013 |
Actual Primary Completion Date : | March 2014 |
Actual Study Completion Date : | April 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Triple Chronotherapy
Total sleep deprivation, Sleep phase advance, and Bright light therapy.
|
Procedure: Triple Chronotherapy
Other Name: Sleep deprivation, Sleep phase advance, and Bright light therapy. |
- Hamilton Depression Rating Scale [ Time Frame: Day prior to total sleep deprivation, and then again over the next 4 consecutive days. ]Change Score of Pre and Post Hamilton depression depression scores
- Columbia Suicide Severity Rating Scale [ Time Frame: Daily throughout the treatment (Days 0-4) ]Change score in Columbia Suicide Severity Rating Scale

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- A current episode of non-psychotic major depression.
- Currently hospitalized.
- Age greater than 18.
- If bipolar illness, must not be a mixed state, and must be on a therapeutic dose of a mood stabilizer.
Exclusion Criteria:
- Urine drug screen positive for cocaine, or current alcohol abuse/dependence that requires detox.
- Current psychosis.
- Panic disorder.
- A history of seizures, uncontrolled severe headaches, stroke, or other neurologic illness that produces either gait abnormalities or a lowered seizure threshold.
- Medical illness that would make wake therapy intolerable, or significant cardiac disease.
- Cataracts, glaucoma, or other intrinsic eye condition.
- Currently taking light sensitizing medications.
- Current pregnancy which is routinely tested for prior to admission.
- Mental retardation, or dementia.
- Untreated sleep disorder such as Obstructive sleep apnea, narcolepsy, or PLMD.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02088580
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 |
Principal Investigator: | Gregory Sahlem, MD | Medical University of South Carolina |
Responsible Party: | Medical University of South Carolina |
ClinicalTrials.gov Identifier: | NCT02088580 |
Other Study ID Numbers: |
Chronotherapy Pilot |
First Posted: | March 17, 2014 Key Record Dates |
Last Update Posted: | October 2, 2015 |
Last Verified: | September 2013 |
Depression Depressive Disorder Bipolar Disorder Behavioral Symptoms |
Mood Disorders Mental Disorders Bipolar and Related Disorders |